249 related articles for article (PubMed ID: 19394761)
21. MRP- and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro.
Khodadadian M; Leroux ME; Auzenne E; Ghosh SC; Farquhar D; Evans R; Spohn W; Zou Y; Klostergaard J
Lung Cancer; 2009 Oct; 66(1):48-57. PubMed ID: 19195736
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of small cell lung cancer in a Japanese cohort.
Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
Santarpia M; Altavilla G; Margeli M; Cirauqui B; Mesiti M; Cavallari V; Ramirez JL; Sanchez-Ronco M; Santarpia L; Taron M; Rosell R
Cancer Invest; 2008 Dec; 26(10):1044-51. PubMed ID: 18798071
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
Gallia GL; Rand V; Siu IM; Eberhart CG; James CD; Marie SK; Oba-Shinjo SM; Carlotti CG; Caballero OL; Simpson AJ; Brock MV; Massion PP; Carson BS; Riggins GJ
Mol Cancer Res; 2006 Oct; 4(10):709-14. PubMed ID: 17050665
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping.
Salido M; Arriola E; Carracedo A; Cañadas I; Rovira A; Espinet B; Rojo F; Arumi M; Serrano S; Albanell J; Sole F
Cancer Genet Cytogenet; 2009 Jun; 191(2):97-101. PubMed ID: 19446745
[TBL] [Abstract][Full Text] [Related]
26. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
27. Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.
Morrow CJ; Gray A; Dive C
FEBS Lett; 2005 Sep; 579(23):5123-8. PubMed ID: 16150444
[TBL] [Abstract][Full Text] [Related]
28. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
29. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer.
Moss AC; Jacobson GM; Walker LE; Blake NW; Marshall E; Coulson JM
Clin Cancer Res; 2009 Jan; 15(1):274-83. PubMed ID: 19118055
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation.
Li P; Ma L; Zhang Y; Ji F; Jin F
Biomed Pharmacother; 2014 Feb; 68(1):7-12. PubMed ID: 24412084
[TBL] [Abstract][Full Text] [Related]
31. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.
Müller CI; Miller CW; Hofmann WK; Gross ME; Walsh CS; Kawamata N; Luong QT; Koeffler HP
Leuk Res; 2007 Jan; 31(1):27-32. PubMed ID: 16764926
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences.
Miyake T; Yoshino K; Enomoto T; Takata T; Ugaki H; Kim A; Fujiwara K; Miyatake T; Fujita M; Kimura T
Cancer Lett; 2008 Mar; 261(1):120-6. PubMed ID: 18180098
[TBL] [Abstract][Full Text] [Related]
33. [Other thoracic cancers. Small-cell lung cancer: an update].
Vermaelen K; van Meerbeeck JP
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S173-82. PubMed ID: 18971843
[TBL] [Abstract][Full Text] [Related]
34. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE
Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491
[TBL] [Abstract][Full Text] [Related]
35. Genetic alterations in the PI3K pathway in prostate cancer.
Sun X; Huang J; Homma T; Kita D; Klocker H; Schafer G; Boyle P; Ohgaki H
Anticancer Res; 2009 May; 29(5):1739-43. PubMed ID: 19443396
[TBL] [Abstract][Full Text] [Related]
36. [Role of SPHK1 regulates multi-drug resistance of small cell lung cancer
and its clinical significance].
Yang L; Hu H; Deng Y; Bai Y
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):769-77. PubMed ID: 25404266
[TBL] [Abstract][Full Text] [Related]
37. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Cui B; Zheng B; Zhang X; Stendahl U; Andersson S; Wallin KL
Int J Oncol; 2009 Feb; 34(2):409-16. PubMed ID: 19148475
[TBL] [Abstract][Full Text] [Related]
38. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Yang X; Tang C; Luo H; Wang H; Zhou X
Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
[TBL] [Abstract][Full Text] [Related]
39. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
40.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
